Online inquiry

IVTScrip™ pT7-VEE-mRNA-Anti-TNFRSF18, MEDI-1873 Vector   (CAT#: GTVCR-WQ1876MR)

This product GTVCR-WQ1876MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA ecoding antibody which targeting TNFRSF18. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
Resistance Ampicillin
Species Homo sapiens
RefSeq NM_004195.3
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 8784
UniProt ID Q9Y5U5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-Anti-TNFRSF18, MEDI-1873 Vector (GTVCR-WQ1876MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ2343MR IVTScrip™ pT7-VEE-mRNA-Anti-IL33, REGN-3500 Vector Vector REGN-3500
GTVCR-WQ913MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD74, CD74-DOX (ADC) Vector Vector CD74-DOX (ADC)
GTVCR-WQ326MR IVTScrip™ pSP6-VEE-mRNA-Anti-PDCD1, AGEN2034 Vector Vector AGEN2034
GTVCR-WQ1776MR IVTScrip™ pT7-VEE-mRNA-Anti-PDCD1, LY3300054 Vector Vector LY3300054
GTVCR-WQ467MR IVTScrip™ pT7-VEE-mRNA-Anti-TNFSF11, AMG162 Vector Vector AMG162
GTVCR-WQ2193MR IVTScrip™ pSP6-VEE-mRNA-Anti-ACVRL1, PF-03446962 Vector Vector PF-03446962
GTVCR-WQ744MR IVTScrip™ pT7-VEE-mRNA-Anti-TNFRSF9, BMS-663513 Vector Vector BMS-663513
GTVCR-WQ1358MR IVTScrip™ pSP6-VEE-mRNA-Anti-C5, h5G1.1HuG2/G4 Vector Vector h5G1.1HuG2/G4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW